Metagenomi Business Summary

Metagenomi Therapeutics, Inc. (MGX) is a precision genetic medicines company that generates revenue through strategic licensing agreements, R&D partnerships, and the development of a proprietary therapeutic pipeline. The company’s business model is centered on its metagenomics-based discovery engine, which identifies novel, naturally occurring genome editing systems—such as compact nucleases and CRISPR-associated transposases—from vast environmental datasets. Its primary business segments include in vivo genome editing for liver-directed diseases, led by its MGX-001 program for hemophilia A, and collaborative programs in cardiometabolic diseases, most notably a multi-target partnership with Ionis Pharmaceuticals. Metagenomi competes directly with established gene-editing firms such as Intellia Therapeutics, Editas Medicine, and CRISPR Therapeutics. Within this landscape, Metagenomi distinguishes itself as a specialized platform provider capable of discovering ultra-compact, site-specific integration tools that overcome the delivery and intellectual property limitations of first-generation CRISPR-Cas9 technologies. The company was founded by Dr. Brian C. Thomas and Dr. Jill Banfield, both pioneers in metagenomics from the University of California, Berkeley, where they spent decades cataloging the microbial world to identify novel biochemical tools. In late 2025, the leadership team underwent a strategic transition, appointing Dr. Jian Irish as President and Chief Executive Officer. Dr. Irish brings a high-pedigree background in biopharmaceutical operations, having previously held executive roles at Kite Pharma (Gilead), Sanofi, and Amgen, where she oversaw the launch of several breakthrough therapies. The executive team is supported by CFO Pamela Wapnick and Board Chair Dr. Willard Dere, a former Amgen executive and professor at the University of Utah. Metagenomi is backed by a notable roster of institutional and strategic investors, including Leaps by Bayer, Bristol Myers Squibb, Novo Nordisk, RA Capital Management, and PFM Health Sciences.